Istanbul, Turkey, 15th September 2009 – Further evidence of the superior antidepressant efficacy of Valdoxan®/Thymanax® (agomelatine) over conventional selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenalin reuptake inhibitor (SNRI) antidepressants was presented today at the Servier satellite symposium on the occasion of the 22nd European College of Neuropsychopharmacology (ECNP) Congress, with educational financial support provided [...]

Valdoxan 25 mg film-coated tablets
Agomelatine
Read all of this leaflet carefully before you start taking this medicine.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, [...]

1. NAME OF THE MEDICINAL PRODUCT
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
3. PHARMACEUTICAL FORM
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
4.2 Posology and method of administration
4.3 Contraindications
4.4 Special warnings and precautions for use
[...]

1. What is the clinical proof of VALDOXAN’s antidepressant efficacy?
The antidepressant efficacy of VALDOXAN has been confirmed in four trials versus placebo, three over the short term and one over the long term. The antidepressant efficacy of VALDOXAN is significantly superior to that of placebo, as mentioned in the Valdoxan SPC, whatever the symptom intensity, [...]

Valdoxan, the first melatonergic antidepressant, presents an innovative receptor profile and mode of action. Valdoxan is a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist. Valdoxan resynchronizes circadian rhythms in animal models of circadian rhythm disruption.
Innovative receptor profile of Valdoxan
Valdoxan is the first melatonergic antidepressant.
Valdoxan is a melatonergic agonist (MT1 and MT2 receptors) and [...]

Valdoxan provides MDD patients with a significant symptomatic relief, as demonstrated by well-documented improvements in depressed mood, anxiety symptoms, and also sleep-wake disturbances (daytime impairment and sleep disturbances).
Efficacy of Valdoxan on depressed mood
Valdoxan has been demonstrated to be significantly effective in relieving depressed mood of patients with MDD, the most characteristic symptom of depression.
In a [...]

Valdoxan’s onset of efficacy has been reported and measured on the Clinical Global Impression-Improvement [CGI-I] scale and Visual Analog Scales [VAS]as early as the first week of treatment. From the first week of treatment, Valdoxan demonstrated to provide significant efficacy in terms of CGI score improvement, as well as VAS score improvement.
Significant improvement in CGI [...]